Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Res. 2014 Oct 8;74(23):6784–6795. doi: 10.1158/0008-5472.CAN-14-0043

Figure 7. Enhanced tumor-free survival and delayed tumor outgrowth following adoptive transfer of phosphopeptide-specific TCR-expressing human CD8 T-cells.

Figure 7

SLM2AAD melanoma tumor-bearing NOD/SCID/IL-2Rγc−/− mice were injected with phosphopeptide-specific TCR-expressing human CD8 T-cells on days 3 and 7, together with 1500 CU/ml IL-2 every other day for 10 days. Control animals received only IL-2. Combo TCR animals received equal amounts of pIRS-2 and pCDC25b-TCR expressing human CD8 T-cells. (n= 5 per group). (A–C) P values were determined by Log-rank (Mantel Cox Test) analysis of control animals to the indicated experimental group through day 25. (D) Data points are mean tumor volumes for each group +/− SD. P values were determined by ANOVA with post-hoc comparisons and no adjustment for multiple comparisons for each day and are in the sequence pCDC25b-TCR, pIRS2, and combo TCR. **, p=0.004, *, p=0.025, ns, p>0.05.